Skip to main content
Full access
Communications and Updates
Published Online: 1 May 2011

Impact of Hypertension and Body Mass Index on Quality of Life in Schizophrenia

To the Editor: We were pleased to read the article by Joseph I. Friedman, M.D., and colleagues in the October 2010 issue of the Journal (1). The article highlights the negative impact of individual cardiovascular risk factors, particularly hypertension, on memory performance in patients with schizophrenia, and suggests that proper treatment of these risk factors may improve cognitive outcomes in these patients.
Pronounced memory deficits have been linked to low quality of life in patients with schizophrenia (2). In recent years, the importance of predictors of quality of life on treatment outcomes among these patients is being recognized (3). We analyzed quality of life among patients with schizophrenia who had hypertension and a body mass index (BMI) >25 as reported in the National Epidemiologic Survey on Alcohol and Related Conditions (N=43,093), a large representative U.S. survey. This survey assessed substance use and mental and physical disorders, including history of schizophrenia, as well as self-reported hypertension and a high BMI in the past 12 months.
We measured quality of life using the 12-item Short-Form Health Survey, a norm-based general health scale, for eight subgroups: participants with schizophrenia with and without hypertension (N=134 and N=252, respectively) or with and without a BMI >25 (N=251 and N=125, respectively) and healthy comparison subjects (participants without schizophrenia) with and without hypertension (N=9,002 and N=33,705, respectively) or with and without a BMI >25 (N=16,983 and N=24,295, respectively). We adjusted all measures for age, gender, education, and ethnicity in all models. We included the vascular risk factor of interest (hypertension or elevated BMI) and the presence or absence of a schizophrenia diagnosis in the main effect model. The interaction between a schizophrenia diagnosis and the vascular risk factor was entered in a second step. We used Taylor linearization to adjust standard errors of means of estimates for complex survey sampling design effects including clustering data, and used the REGRESS procedure in the SUDAAN software package (4).
Hypertension, but not a BMI >25, had a significant negative impact on quality of life in patients with schizophrenia (Figure 1). We found no significant interaction between schizophrenia and a BMI >25 on quality of life.
FIGURE 1. Health-Related Quality of Life for Patients With Schizophrenia and Comparison Subjects With and Without Hypertension and With and Without a Body Mass Index (BMI) Over 25
*p<0.001. **p<0.0001.
Friedman et al. (1) stress the importance of addressing individual cardiovascular risk factors in patients with schizophrenia. The dissociation between the effect of hypertension and a BMI >25 on quality of life in these patients is in line with this. Our findings stress the importance of screening for and treating hypertension in patients with schizophrenia, given its association with a poorer quality of life in this patient population.

Footnote

Accepted for publication in March 2011.

References

1.
Friedman JI, Wallenstein S, Moshier E, Parrella M, White L, Bowler S, Gottlieb S, Harvey PD, McGinn TG, Flanagan L, Davis KL: The effects of hypertension and body mass index on cognition in schizophrenia. Am J Psychiatry 2010; 167:1232–1239
2.
Ranganath C, Minzenberg MJ, Ragland JD: The cognitive neuroscience of memory function and dysfunction in schizophrenia. Biol Psychiatry 2008; 64:18–25
3.
Narvaez JM, Twamley EW, McKibbin CL, Heaton RK, Patterson TL: Subjective and objective quality of life in schizophrenia. Schizophr Res 2008; 98:201–208
4.
Research Triangle Institute: Software for Survey Data Analysis (SUDAAN), version 9.0. Research Triangle Park, NC, Research Triangle Institute, 2004

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 552 - 553
PubMed: 21536705

History

Accepted: March 2011
Published online: 1 May 2011
Published in print: May 2011

Authors

Affiliations

Shaul Lev-Ran, M.D.
Yann Le Strat, M.D.
Bernard Le Foll, M.D., Ph.D.

Funding Information

Dr. Le Foll has received research grants from Pfizer and has performed consulting work for Richter Pharmaceuticals. The remaining authors report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share